Lung Cancer Clinical Trial
Idylla EGFR Lung Trial
Summary
This retrospective, observational study will compare the results of a BioCartis' EGFR mutation test on the Idylla platform with test results from SoC pathology results from tissue biopsies in the same setting. A comparable rapid testing platform for EGFR may serve as a more accessible means to diagnose, and overall, more patients treated successfully with targeted therapies. Up to 150 samples will be tested and compared with existing results.
Full Description
This study will compare the results of a BioCartis' EGFR mutation test on theIdylla platform with test results from standard of care (SoC) pathology results from tissue biopsies. The Idyllaâ„¢ EGFR Mutation Test, performed on the BioCartis Idyllaâ„¢ System, is an in vitro diagnostic test for the qualitative detection of exon 18, exon 20, and exon 21 mutations. Additionally, exon 19 deletions and exon 20 insertions in the EGFR oncogene. A rapid testing platform for EGFR may serve as a more accessible means to diagnose, and overall, more patients treated successfully with targeted therapies.
Eligibility Criteria
Inclusion Criteria:
Patients diagnosed with primary lung cancer
Data from primary diagnosis must be included in pathology report or data entry.
Detailed pathology report included for all samples
Exclusion Criteria:
Limited or no tissue available
Only tissue available is from fine needle aspiration
Tissue blocks older than 5 years old
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Orlando Florida, 32827, United States More Info
Principal Investigator
How clear is this clinincal trial information?